Followers | 753 |
Posts | 16674 |
Boards Moderated | 0 |
Alias Born | 05/30/2007 |
![](https://investorshub.advfn.com/uicon/102020.png?cb=1718624920)
Sunday, August 07, 2022 11:15:48 AM
The analyst quotes: "We reiterate our Buy rating and $310 price target. Our target is based on sum-of-the-parts including: (1) a clinical NPV model of assets in Phase 2 development or greater (currently 20 out of more than 200 assets under development); and (2) NPV of current revenues based on our projections for royalties, material sales, and collaborative revenue. We believe that Ligand's strong cash position should prove incremental in driving future value for the company based on acquisitions and signed partnerships for current technology platforms such as liver targeting, Captisol, and especially OmniAb. We also point out that a significant number of assets are not included in our valuation as well as the growing number of candidates being generated from OmniAb partnerships. Our clinical NPV model allows us to flex multiple assumptions affecting a drug's potential commercial profile. Overall, we believe that our valuation projections should be supported by continued news flow out of partnered assets, new deals, and continued business development activities. Factors that could impede reaching our price target include failed or inconclusive clinical trials, insufficient traction of commercialized drugs, and or inability of the company to secure adequate funding to progress its drugs through the development pathway."
For an analyst ratings summary and ratings history on Ligand Pharma click here. For more ratings news on Ligand Pharma click here.
By Vlad Schepkov | Vlad@StreetInsider.com
https://www.streetinsider.com/Analyst+Comments/Ligand+%28LGND%29+Reiterated+at+Buy+by+H.C.+Wainwright%2C+Strong+Partnerships+and+Cash+Position+Should+Drive+Future+Value/19644534.html
Recent LGND News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 09:10:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 08:02:22 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/09/2024 08:52:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 11:38:30 AM
- Lifecore Biomedical Announces Cooperation Agreement with 22NW • GlobeNewswire Inc. • 07/01/2024 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/03/2024 08:03:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:03:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2024 12:00:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 11:59:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 09:45:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/16/2024 09:39:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2024 11:34:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2024 10:01:57 PM
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 05/15/2024 06:45:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2024 11:42:38 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/09/2024 08:11:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 06:27:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:28:44 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 11:12:20 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/01/2024 09:09:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:50:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:50:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:50:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:49:56 PM
FEATURED Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • Jul 29, 2024 9:07 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM